Author:
Ruß H. M.,Kuhn W.,Przuntek H.
Publisher
Springer Berlin Heidelberg
Reference10 articles.
1. Bade B, Christ W, Rakow D, Coper H (1976) Comparison of COMT from rat brain, erythrocytes and liver. Life Sci 19: 1833–1844
2. Da Prada M (1988) Dopa and 3-O-methyldopa plasma levels after benserazide alone or together with madopar and the new COMT-inhibitor Ro 41–0960. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Key topics in brain research. Springer, Wien New York
3. Ericsson AD (1971) Potentation of the L-dopa effect in man by use of COMT inhibitors. J Neurol Sci 14: 193–197
4. Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN (1987) 3-O-methyldopa and motor fluctuations in Parkinson’s disease. Neurology 37: 856–859
5. Fahn S, Comi R, Snider SR, Prasad ALN (1979) Effect of a COMT inhibitor, U-0521., with levadopa administration. Biochem Pharmacol 28: 1221–1225